## SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 10-C

Report by Issuer of Securities Quoted on NASDAQ Interdealer Quotation System Filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 and Rule 13a-17 or 15d-17 thereunder

NORTH AMERICAN BIOLOGICALS, INC. (Exact name of issuer as specified in charter)

5800 Park of Commerce Boulevard, N.W., Boca Raton, Florida 33487 (Address of principal executive offices)

Issuer's telephone number, including area code: (407) 989-5800

I. CHANGE IN NUMBER OF SHARES OUTSTANDING

Indicate any change (increase or decrease) of 5% or more in the number of shares outstanding:

- 1. Title of security: Common Stock, par value \$.10 per share.
- 2. Number of shares outstanding before the change: 19,552,479.
- 3. Number of shares outstanding after the change: 33,824,261.
- 4. Effective date of change: November 29, 1995.
- 5. Method of change: Issuance of additional shares.

Brief description of transaction: On November 29, 1995, Univax Biologics, Inc. merged with and into the issuer in a stock-for-stock transaction resulting in the issuance of approximately 14,271,782 shares of Common Stock.

Date: December 1, 1995

/s/ Alfred J. Fernandez
(Officer's signature)

Senior Vice President and Chief Financial Officer
(Officer's title)